More importantly, we developed the precision treatment scheme on transgenic mouse model of autochthonous lung cancer: Combination of pan-KRAS inhibitor, NF-κB inhibitor and PD-1 inhibitor effectively shrank KRAS mutation positive/ZNF24-low lung cancers. This evidence concerns the gene KRAS and lung carcinoma.